Kelun-Biotech's Phase III lung cancer trial meets endpoint
July 15, 2026 | 11:11
Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with pembrolizumab met its primary endpoint as a first-line treatment for PD-L1-negative non-squamous lung cancer.
Mobile Version